Product Description
Ranolazine (Ranexa), a piperazine derivative, is a new antianginal agent approved for the treatment of chronic stable angina pectoris for use as combination therapy when angina is not adequately controlled with other antianginal agents. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16620147/)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Greece
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Atrial Fibrillation
Phase 2: Angina Pectoris|Angina, Stable|Cardiomyopathy, Hypertrophic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-514677-22-00 | P3 |
Unknown Status |
Atrial Fibrillation |
2025-06-30 |
|
| IV-FLEC | P3 |
Active, not recruiting |
Atrial Fibrillation |
2023-02-17 |
|
| Ranolazine microvascular dysfunction HCM | P2 |
Active, not recruiting |
Cardiomyopathy, Hypertrophic |
2019-04-06 |
|
| Ranolazine - AOUPi/001 | P2 |
Active, not recruiting |
Angina, Stable |
2016-10-24 |